MyoKardia Eyes $86 Million IPO

Published: Sep 29, 2015

Early-stage Peninsula heart drug developer MyoKardia Inc. wants to raise $86.25 million in an initial public offering, the company said Monday, even as Wall Street scurries over fears of controls on drug pricing.

An IPO would be the latest winning exit for Third Rock Ventures, which was the biggest venture investors in Bay Area biotech startups as others left the industry during and after the Great Recession.

Led by CEO Tassos Gianakakos, MyoKardia is targeting hypertrophic cardiomyopathy, or HCM.

Help employers find you! Check out all the jobs and post your resume.

Back to news